MANKIND vs MEDICAMEQ: Stock Comparison
MANKIND PHARMA is the larger company by market capitalisation. MANKIND PHARMA shows a higher ROE, a higher ROCE and a higher net margin, while MEDICAMEN BIOTECH shows a lower P/E, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MANKIND leads 6; MEDICAMEQ leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| Live Price | ₹2,327.9 | ₹270.25 |
| Day Change | -1.73% | 4.18% |
| Volume | 1.22 L | 1.18 L |
| 52-Week High | ₹2,674 | ₹447.65 |
| 52-Week Low | ₹1,909.7 | ₹212.4 |
| Distance from 52W High | -12.94% | -39.63% |
Valuation
| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| Market Cap | ₹96,168 Cr | ₹369 Cr |
| P/E Ratio | 47.96x | 27.39x |
| P/B Ratio | 6.03x | 1.08x |
| EPS | ₹13.52 | ₹1.56 |
| Book Value | ₹401 | ₹203.17 |
| Dividend Yield | 0% | 0.38% |
Growth
| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.8% | 80.2% |
| EPS Growth (TTM YoY) | 31.7% | 44.7% |
| Qtr Sales Growth | -26.46% | 9.22% |
| Qtr Profit Growth | -2.72% | -26.94% |
Profitability & Leverage
| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| ROE | 11.7% | 3.36% |
| ROCE | 11.17% | 4.09% |
| Net Margin | 13.34% | 5.21% |
| Operating Margin | 20.73% | 8.01% |
| Debt to Equity | 0.38x | 0.13x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | MANKIND | MEDICAMEQ |
|---|---|---|
| Promoter Holding | 72.63%▼ 0.03 pp | 40.46% |
| FII Holding | 9.45%▼ 0.79 pp | 0.07%▼ 0.03 pp |
| DII Holding | 15.39%▲ 0.93 pp | 0.4%▲ 0.4 pp |
| Public Holding | 2.53%▼ 0.11 pp | 59.02%▼ 0.37 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MANKIND PHARMA and MEDICAMEN BIOTECH.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.